Login
AC Immune SA logo

AC Immune SA

acimmune.com

What Do They Do?

Develops medicines and brain-imaging agents for neurodegenerative diseases, partnering with pharmaceutical companies.

How Do They Make Money?

Pharmaceutical partners pay for rights to product candidates and intellectual property through upfront license fees, development, regulatory or commercial milestone payments, research and clinical service fees, and royalties on licensed-product sales. AC Immune earns service fees as it performs the work, and upfront license fees when rights are transferred.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical partners license rights to product candidates and intellectual property; some also contract AC Immune for research and clinical services.

How Are They Changing?

Strategic emphasis The older strategy described diagnostics as a distinct pillar alongside Alzheimer’s drug development and expansion into Parkinson’s and other disorders. The latest frames active immunotherapies and small molecules aimed at intracellular disease processes as core product-development drivers, with partnerships supporting business development.

Who Do They Compete With?

Competes with Biogen, Eisai, Eli Lilly, Axon Neuroscience, Nuravax, TheraVac, Araclon Biotech, Vaxxinity, Alzinova, Aprinoia, Lantheus, Genentech, Roche, Janssen, UCB, Ventyx, NodThera, Ventus, Zydus, and TauRx

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support